|
|
Article: FDA Approves Single-Tablet HIV Drug From Gilead, BMS.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
A 2004 joint venture between Gilead Sciences Inc. and Bristol-Myers Squibb Co. has led to the approval of the first once-daily, triple-drug regimen for HIV-1 patients.
The FDA gave the nod to Atripla, which combines Foster City, Calif.-based Gilead's Truvada, a fixed-dose product comprising Viread (tenofovir disoproxil) and Emtriva (emtricitabine), with New York-based BMS' Sustiva (efavirenz).
All three ingredients work by blocking reverse transcriptase, an enzyme needed for HIV replication.
Atripla, which can be administered as a stand-alone therapy or in combination with other antiretrovirals, is expected to be available ...